Helicobacter pylori: Novel Therapies
The ideal therapy for Helicobacter pylori would cure the infection without resulting in the development of antibiotic resistance. Current therapies have variable cure rates; the reasons for treatment failure include bacterial resistance and poor compliance. Some antibiotics, such as furazolidone, ma...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1999-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1999/485237 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568397956644864 |
|---|---|
| author | Eric Drouin |
| author_facet | Eric Drouin |
| author_sort | Eric Drouin |
| collection | DOAJ |
| description | The ideal therapy for Helicobacter pylori would cure the infection without resulting in the development of antibiotic resistance. Current therapies have variable cure rates; the reasons for treatment failure include bacterial resistance and poor compliance. Some antibiotics, such as furazolidone, may be affordable agents to treat this infection worldwide. New proton pump inhibitors, such as rabeprazole, can potentiate antibiotics. Nutriceuticals and probiotics demonstrate interesting in vitro activity against H pylori. Children rarely have symptoms to this infection and, therefore, are a suitable group in which to assess different nonaggressive therapies. |
| format | Article |
| id | doaj-art-f14a86f3ee524a529e257ada9fee1816 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1999-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-f14a86f3ee524a529e257ada9fee18162025-02-03T00:59:10ZengWileyCanadian Journal of Gastroenterology0835-79001999-01-0113758158310.1155/1999/485237Helicobacter pylori: Novel TherapiesEric Drouin0Division of Gastroenterology, Hôpital Ste-Justine, University of Montreal, Montreal, Quebec, CanadaThe ideal therapy for Helicobacter pylori would cure the infection without resulting in the development of antibiotic resistance. Current therapies have variable cure rates; the reasons for treatment failure include bacterial resistance and poor compliance. Some antibiotics, such as furazolidone, may be affordable agents to treat this infection worldwide. New proton pump inhibitors, such as rabeprazole, can potentiate antibiotics. Nutriceuticals and probiotics demonstrate interesting in vitro activity against H pylori. Children rarely have symptoms to this infection and, therefore, are a suitable group in which to assess different nonaggressive therapies.http://dx.doi.org/10.1155/1999/485237 |
| spellingShingle | Eric Drouin Helicobacter pylori: Novel Therapies Canadian Journal of Gastroenterology |
| title | Helicobacter pylori: Novel Therapies |
| title_full | Helicobacter pylori: Novel Therapies |
| title_fullStr | Helicobacter pylori: Novel Therapies |
| title_full_unstemmed | Helicobacter pylori: Novel Therapies |
| title_short | Helicobacter pylori: Novel Therapies |
| title_sort | helicobacter pylori novel therapies |
| url | http://dx.doi.org/10.1155/1999/485237 |
| work_keys_str_mv | AT ericdrouin helicobacterpylorinoveltherapies |